Navigation Links
SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa
Date:4/17/2008

NORCROSS, Ga., April 17 /PRNewswire/ -- The SurgiLance safety lancet, an industry-leading medical safety product manufactured by MediPurpose, has been selected for inclusion in an HIV kit distributed throughout Africa by Nigerian-based Bundi International Diagnostics. Long established in the Americas and Europe, SurgiLance safety lancets are now part of a major testing initiative designed to stem the tide of HIV/AIDS on the African continent.

A critical component of the fight against AIDS, HIV testing initiatives identify those at risk for developing AIDS and make early intervention and treatment possible. Last year alone, more than 1.7 million adults and children became infected with HIV in Sub-Saharan Africa. In this region most devastated by the AIDS epidemic, an astonishing 1.6 million people lost their lives to AIDS in 2007.

"This new relationship with Bundi International Diagnostics underscores our commitment to those front-line medical professionals committed to global health initiatives like HIV/AIDS prevention," says MediPurpose CEO Patrick Yi. "A growing number of test kit manufacturers have chosen the SurgiLance safety lancet for their point-of-care test kits which are used both in medical facilities and in the field," added Randy Prather, MediPurpose VP for Sales and Marketing. "In addition to their use in HIV test kits, SurgiLance safety lancets can be used to test for Hepatitis and Chagas and are commonly used in glucose and cholesterol testing."

Manufactured in Nigeria, Bundi HIV test kits are widely used in state and federal hospitals, non-governmental organizations, clinics, voluntary counseling and testing centers. The Bundi kit contains all items necessary to perform HIV testing. The test kit can be refrigerated or stored at room temperature, making it a convenient choice even for poorly-equipped laboratories and field locations without lab facilities or electricity.

"The SurgiLance safety lancet is a critical component of the Bundi Rapid HIV-1/2 Test Kit and sets us apart from other HIV test kits," says Bundi president Robert Udeagha. "The SurgiLance safety lancet allows consistent depth of penetration, provides optimal blood flow in mere seconds, delivers a quality blood sample and is virtually pain-free for patients undergoing HIV testing. Best of all," says Udeagha, "the inclusion of SurgiLance safety lancets completely eliminates the dangers associated with accidental needle stick, which is one means of HIV transmission."

About MediPurpose

MediPurpose designs, manufactures and markets innovative healthcare solutions valued by its customers. The company is known for introducing quality safety medical devices that protect healthcare professionals from sharps injury. Founded in 1999, the company achieved rapid success with its SurgiLance safety lancet, quickly becoming one of the top leaders in the US safety lancet market and establishing solid distribution channels worldwide.

As a globally recognized innovator, MediPurpose has developed a menu of services to assist inventors and growing medical device companies successfully design, patent, manufacture and sell their products. MediPurpose maintains offices in the US, Singapore, the UK, France and Spain.

For more information on MediPurpose, visit http://www.medipurpose.com .


'/>"/>
SOURCE MediPurpose
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardiac Safety Study of Stinger S-200 Published
2. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
3. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
9. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
10. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
11. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/5/2017)... , June 5, 2017 Kohll,s Pharmacy ... the United States . The Raizer is ... a fallen person up to an almost-standing position ... and operated by one assistant and does not ... is simple enough that a child can operate it, ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... 2017 , ... An increase in wetter weather in the Northern California area ... that; a humdinger of an allergy season. A relief from drought conditions is most ... grass and weed pollen. , “Our patients have been reporting the typical allergy ...
(Date:6/25/2017)... ... ... is Men’s Health Month and the focus is on prostate cancer. Second only ... and the third most common cause of cancer related death today; lung cancer remains in ... diagnosed with prostate cancer during his lifetime. Those at highest risk are men ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and ... so that visits to the dentist fit into their patients’ busy lifestyles. Dental365 ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island Quality Institute ... Alerts and Dashboards, an innovative new service enabling healthcare providers to proactively coordinate ... Alerts and Dashboards provide near real-time data about patients admitted to and/or discharged ...
(Date:6/23/2017)... ... June 23, 2017 , ... Yesterday, ... proposed healthcare bill to repeal and replace the Affordable Care Act (ACA). Like ... make significant cuts to Medicaid, a public health insurance program for low-income children, ...
Breaking Medicine News(10 mins):